BioCorRx Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BICX research report →
Price Chart
About the company
BioCorRx Inc. (BICX), through its various operations, is dedicated to creating and delivering therapeutic solutions for individuals struggling with substance dependence and related health conditions across the United States. Among its core offerings is the BioCorRx recovery program, an innovative, non-addictive treatment model.
- CEO
- Lourdes Felix
- IPO
- 2010
- Employees
- 3
- HQ
- Anaheim, CA, US
Get TickerSpark's AI analysis on BICX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.33M
- P/E
- -1.59
- PEG
- -0.01
- P/S
- 6.78
- P/B
- -0.48
- EV/EBITDA
- -3.89
- Div Yield
- 0.00%
- Gross Margin
- 61.07%
- Op Margin
- -622.28%
- Net Margin
- -401.89%
- ROE
- 26.14%
- ROIC
- 99.54%
Latest fiscal year · YoY change
- Revenue
- $797.24K+10301.1%
- Gross Profit
- $691.38K+11426.9%
- Op Income
- $-4,831,642
- Net Income
- $-3,440,146+32.6%
- EPS
- $-0.19+61.2%
- OCF Growth
- -109.6%
- FCF Growth
- -109.6%
- 52W High
- $1.28
- 52W Low
- $0.15
- 50D MA
- $0.24
- 200D MA
- $0.32
- Beta
- 0.21
- RSI (14)
- 43
- Avg Volume
- 3.33K
No earnings-call transcripts are available for BICX yet.
- Free Float
- 71.0%
- Shares Outstanding
- 26.40M
- Float Shares
- 18.74M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 31, 24 | Lucido Louis C. | other | 13,158 |
| Dec 31, 24 | Lucido Louis C. | other | 43,860 |
| Nov 29, 24 | Lucido Louis C. | other | 55,494 |
| Oct 31, 24 | Lucido Louis C. | other | 55,556 |
| Oct 14, 24 | Lucido Louis C. | other | 1,105,218 |
| Sep 30, 24 | Lucido Louis C. | other | 15,625 |
| Sep 30, 24 | Lucido Louis C. | other | 52,085 |
| Aug 30, 24 | Lucido Louis C. | other | 55,559 |
| Jul 31, 24 | Lucido Louis C. | other | 32,092 |
| Apr 24, 24 | Lucido Louis C. | other | 460,477 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BICX coverage
Recent articles, reports, and earnings notes.
No research on BICX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BICX report →Biocorrx Inc. (OTCMKTS:BICX) Stock Short Interest Drops 44.3%
defenseworld.net · Sep 30
Short Interest in Biocorrx Inc. (OTCMKTS:BICX) Expands By ∞
defenseworld.net · Sep 15
Biocorrx Inc. (OTCMKTS:BICX) Short Interest Update
defenseworld.net · Aug 15
Biocorrx Inc. (OTCMKTS:BICX) Short Interest Update
defenseworld.net · Jul 30
Head-To-Head Analysis: Biocorrx (OTCMKTS:BICX) and IceCure Medical (NASDAQ:ICCM)
defenseworld.net · Mar 27
GoodRx (NASDAQ:GDRX) versus Biocorrx (OTCMKTS:BICX) Critical Comparison
defenseworld.net · Mar 23
Biocorrx (OTCMKTS:BICX) Stock Price Crosses Above 50 Day Moving Average – Here’s What Happened
defenseworld.net · Mar 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.